The aims of this study were three-fold: to identify the most reliable, reproducible and time efficient method of Ki-67 scoring using the recommendations of the International Ki-67 in Breast Cancer Working Group as a guide;8 to determine the correlation between Ki-67 and known pathological prognostic variables; and to investigate whether higher Ki-67 expression is associated with a shorter cancer-specific survival and, therefore, has clinical value as a biomarker in endometrial cancer trials. This evidence concerns the gene MKI67 and breast carcinoma.